Ashley Olson1, Norbert Bannert2, Anders Sönnerborg3, Carmen de Mendoza4, Matthew Price5,6, Robert Zangerle7, Marie-Laure Chaix8, Maria Prins9, Anne-Marte Bakken Kran10,11, John Gill12, Dimitrios Paraskevis13, Kholoud Porter1. 1. University College London, London, UK. 2. Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany. 3. Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. 4. Department of Internal Medicine, Puerta de Hierro Research Institute and University Hospital, Majadahonda, Madrid, Spain. 5. International AIDS Vaccine Initiative, New York, New York. 6. Department of Epidemiology and Biostatistics, University of California San Francisco, California, USA. 7. Department of Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria. 8. Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France. 9. Public Health Service of Amsterdam, Cluster of Infectious Diseases, Amsterdam, the Netherlands. 10. Department of Microbiology, Oslo University Hospital. 11. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 12. University of Calgary, Calgary, Alberta, Canada. 13. Department of Hygiene, Epidemiology and Medical Statistics, University of Athens, Athens, Greece.
Abstract
BACKGROUND: The rate of transmitted drug resistance (TDR) may increase with wider use of antiretroviral therapy and can contribute to therapeutic failure. We analysed time trends in TDR among HIV seroconverters. METHODS: Using CASCADE data of individuals with well estimated dates of HIV seroconversion, we examined HIV nucleotide sequences collected prior to antiretroviral therapy use from 1996-2012. All samples were taken within 12 months of testing HIV positive. Using logistic regression, we examined the association between TDR and year of seroconversion, adjusting for confounders. RESULTS: Of 4717 individuals seroconverting between 1996 and 2012, median (IQR) age at seroconversion was 33 (27, 39) years. The majority (3839; 92%) were male, mainly exposed through MSM (3767; 80%), and infected with subtype B (3464; 73%). Overall, 515 (11%) individuals had at least one drug resistance-related mutation; 280 individuals with nucleoside reverse transcriptase, 185 with nonnucleoside reverse transcriptase, and 144 with protease inhibitor mutations. Estimated TDR prevalence was 19.4% (8.2, 36.0) in 1996, significantly decreasing to 8.5% (5.9, 11.9) in 2012 [odds ratio (OR; 95% confidence interval (CI)) = 0.92 (0.90, 0.95) per year increase]. Individuals exposed through sex between men and women were significantly less likely to have been infected with a drug-resistant strain [OR (95% CI) = 0.59 (0.41, 0.87) compared with MSM], and there was marginal evidence that sampling during acute infection was associated with higher odds of resistance [OR (95% CI) = 1.20 (0.97, 1.7), P = 0.093] compared with later sampling. CONCLUSION: TDR has decreased over calendar time although a significant proportion of new infections still carry resistance-related mutations.
BACKGROUND: The rate of transmitted drug resistance (TDR) may increase with wider use of antiretroviral therapy and can contribute to therapeutic failure. We analysed time trends in TDR among HIV seroconverters. METHODS: Using CASCADE data of individuals with well estimated dates of HIV seroconversion, we examined HIV nucleotide sequences collected prior to antiretroviral therapy use from 1996-2012. All samples were taken within 12 months of testing HIV positive. Using logistic regression, we examined the association between TDR and year of seroconversion, adjusting for confounders. RESULTS: Of 4717 individuals seroconverting between 1996 and 2012, median (IQR) age at seroconversion was 33 (27, 39) years. The majority (3839; 92%) were male, mainly exposed through MSM (3767; 80%), and infected with subtype B (3464; 73%). Overall, 515 (11%) individuals had at least one drug resistance-related mutation; 280 individuals with nucleoside reverse transcriptase, 185 with nonnucleoside reverse transcriptase, and 144 with protease inhibitor mutations. Estimated TDR prevalence was 19.4% (8.2, 36.0) in 1996, significantly decreasing to 8.5% (5.9, 11.9) in 2012 [odds ratio (OR; 95% confidence interval (CI)) = 0.92 (0.90, 0.95) per year increase]. Individuals exposed through sex between men and women were significantly less likely to have been infected with a drug-resistant strain [OR (95% CI) = 0.59 (0.41, 0.87) compared with MSM], and there was marginal evidence that sampling during acute infection was associated with higher odds of resistance [OR (95% CI) = 1.20 (0.97, 1.7), P = 0.093] compared with later sampling. CONCLUSION: TDR has decreased over calendar time although a significant proportion of new infections still carry resistance-related mutations.
Authors: Jessica M Fogel; Mariya V Sivay; Vanessa Cummings; Ethan A Wilson; Stephen Hart; Theresa Gamble; Oliver Laeyendecker; Reinaldo E Fernandez; Carlos Del Rio; D Scott Batey; Kenneth H Mayer; Jason E Farley; Laura McKinstry; James P Hughes; Robert H Remien; Chris Beyrer; Susan H Eshleman Journal: AIDS Date: 2020-01-01 Impact factor: 4.632
Authors: Brunna M Alves; Juliana D Siqueira; Marianne M Garrido; Ornella M Botelho; Isabel M Prellwitz; Sayonara R Ribeiro; Esmeralda A Soares; Marcelo A Soares Journal: Viruses Date: 2017-12-19 Impact factor: 5.048
Authors: Vlad Novitsky; Jon Steingrimsson; Fizza S Gillani; Mark Howison; Su Aung; Matthew Solomon; Cindy Y Won; Amy Brotherton; Rajeev Shah; Casey Dunn; John Fulton; Thomas Bertrand; Anna Civitarese; Katharine Howe; Theodore Marak; Philip Chan; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor Journal: Open Forum Infect Dis Date: 2021-12-07 Impact factor: 4.423